

4 June 2008

**Akers Biosciences, Inc.**  
("ABI" or the "Company")

**Option Agreement**

Akers Biosciences, Inc., a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has entered into put and call options (the "Options") with a consortium of private investors, acting through Saltburn Limited (the "Investor"), a company incorporated in the Channel Islands, to invest in aggregate up to £2.275m in ABI through the subscription of up to 17,500,000 new common shares in the Company. The Options may be exercised by the Company up to and including 6 June 2008 and by the Investor thereafter until 16 June 2008.

Further details of the Options and the Company's use of proceeds, if exercised, will be announced in due course.

**Enquiries:**

Thomas A. Nicolette  
President and CEO  
Tel. +1 856 848 8698

Ben Simons or Eleanor Williamson  
M:Communications  
Tel. +44 (0)20 7153 1540

Alasdair Younie  
Arbutnot Securities Limited  
Tel. +44 (0)20 7012 2139